Lauxera Capital Partners is an independent, international investment fund focused on growth companies in Healthtech, investing capital and expertise to improve the efficiency of the Healthtech system. The firm targets commercial-stage healthtech businesses at the early profitability stage across Europe and North America.
Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $99.7M (across 9 rounds with reported amounts).
Portfolio
10
Fund Size
—
Top Stage
Series C
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
15 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| BBridge To Life | Series C | $110M | Aug 2026 |
| BBridge To Life | Bridge | — | Aug 2026 |
| VVerdot | Growth | — | Jan 2025 |
 OrganOx | Unknown | $142M | Jan 2025 |
| SSynovo Group | Growth | — | Sep 2024 |
 CareSyntax | Series C | $180M | Aug 2024 |
 Natural Cycles | Series C | — | May 2024 |
 Lifen | Series C | — | Nov 2021 |
| BBridge To Life | Series A | $56M | Aug 2021 |
 Lumicks | Series D | $93M | Apr 2021 |
| LLumicks B.V. | Series D | $93M | Apr 2021 |
| Lumicks | Series D | $93M | Jan 2021 |
| CareSyntax | Series C | $100M | Jan 2021 |
| Natural Cycles | Series B | $30M | Jan 2016 |
| AAntaros Medical | Growth | — | — |
Top Co-Investors
Soleus Capital4 shared
Pura Vida Investments3 shared
T. Rowe Price3 shared
Farallon Capital Management3 shared
Gilde Healthcare3 shared
Perceptive Advisors3 shared
Headline2 shared
Plug and Play Tech Center2 shared
Intel Capital2 shared
Rezayat Investments2 shared
PFM Health Sciences2 shared
Optum Ventures2 shared
J.P. Morgan1 shared
JPMorgan Chase & Co.1 shared
Point72 Private Investments1 shared
Serena1 shared
Partech Africa1 shared
UI Investissement1 shared
Creadev1 shared
EQT Ventures1 shared
Last updated: 20 October 2026